Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SYRS |
---|---|---|
09:32 ET | 3589 | 6.04 |
09:34 ET | 2000 | 6.196 |
09:36 ET | 3981 | 6.105 |
09:41 ET | 2722 | 6.1 |
09:45 ET | 135 | 6.138 |
09:52 ET | 100 | 6.125 |
09:54 ET | 600 | 6.13 |
09:56 ET | 447 | 6.09 |
10:06 ET | 350 | 6.03 |
10:10 ET | 778 | 6.0074 |
10:21 ET | 195 | 6.0975 |
10:30 ET | 100 | 6.1 |
10:32 ET | 212 | 6.075 |
10:39 ET | 1320 | 6.13 |
10:42 ET | 654 | 6.1005 |
10:44 ET | 200 | 6.1005 |
10:46 ET | 200 | 6.13 |
10:48 ET | 100 | 6.1262 |
10:51 ET | 100 | 6.138 |
10:53 ET | 2227 | 6.1 |
10:55 ET | 1106 | 6.1 |
10:57 ET | 1125 | 6.095 |
11:04 ET | 125 | 6.0846 |
11:09 ET | 106 | 6.13 |
11:20 ET | 200 | 6.12 |
11:22 ET | 300 | 6.114 |
11:24 ET | 100 | 6.1137 |
11:26 ET | 1734 | 6.06 |
11:29 ET | 125 | 6.0819 |
11:33 ET | 1391 | 6.06 |
11:40 ET | 2236 | 6.02 |
11:44 ET | 106 | 6.04 |
11:45 ET | 100 | 6.07 |
11:47 ET | 1169 | 6.05 |
11:49 ET | 300 | 6.052 |
11:51 ET | 200 | 6.0646 |
11:56 ET | 100 | 6.065 |
11:58 ET | 3791 | 6 |
12:00 ET | 2298 | 6.0028 |
12:02 ET | 3350 | 6.02 |
12:03 ET | 2779 | 6.01 |
12:09 ET | 1048 | 6.05 |
12:12 ET | 100 | 6.066 |
12:20 ET | 200 | 6.1 |
12:27 ET | 100 | 6.1 |
12:30 ET | 177 | 6.096 |
12:38 ET | 499 | 6.1094 |
12:43 ET | 1963 | 6.075 |
12:45 ET | 300 | 6.08 |
12:48 ET | 100 | 6.0685 |
12:50 ET | 100 | 6.0574 |
12:52 ET | 966 | 6.045 |
12:57 ET | 500 | 6.0139 |
01:08 ET | 800 | 6.012 |
01:10 ET | 600 | 6.01 |
01:14 ET | 500 | 6.03 |
01:17 ET | 708 | 6.034 |
01:19 ET | 240 | 6.0256 |
01:26 ET | 1599 | 6.06 |
01:28 ET | 1601 | 6.0819 |
01:30 ET | 800 | 6.085 |
01:32 ET | 200 | 6.085 |
01:33 ET | 385 | 6.09 |
01:46 ET | 400 | 6.09 |
01:50 ET | 300 | 6.0854 |
01:53 ET | 400 | 6.08 |
01:57 ET | 1047 | 6.11 |
02:02 ET | 200 | 6.12 |
02:04 ET | 200 | 6.12 |
02:06 ET | 919 | 6.115 |
02:08 ET | 100 | 6.115 |
02:11 ET | 1000 | 6.11 |
02:18 ET | 100 | 6.13 |
02:20 ET | 300 | 6.13 |
02:24 ET | 200 | 6.14 |
02:26 ET | 1752 | 6.11 |
02:27 ET | 100 | 6.102 |
02:29 ET | 100 | 6.1113 |
02:31 ET | 100 | 6.1083 |
02:33 ET | 1200 | 6.11 |
02:36 ET | 100 | 6.12 |
02:38 ET | 3628 | 6.13 |
02:40 ET | 521 | 6.11 |
02:44 ET | 100 | 6.105 |
02:47 ET | 100 | 6.105 |
02:51 ET | 925 | 6.11 |
02:56 ET | 200 | 6.09 |
02:58 ET | 400 | 6.11 |
03:05 ET | 200 | 6.09 |
03:07 ET | 1600 | 6.095 |
03:09 ET | 200 | 6.1 |
03:12 ET | 400 | 6.1 |
03:14 ET | 3087 | 6.08 |
03:18 ET | 700 | 6.0807 |
03:20 ET | 1477 | 6.1053 |
03:21 ET | 200 | 6.11 |
03:23 ET | 100 | 6.1 |
03:25 ET | 614 | 6.12 |
03:27 ET | 509 | 6.12 |
03:30 ET | 100 | 6.12 |
03:32 ET | 100 | 6.12 |
03:34 ET | 1636 | 6.108 |
03:36 ET | 900 | 6.07 |
03:38 ET | 500 | 6.08 |
03:39 ET | 1096 | 6.08 |
03:41 ET | 2846 | 6.08 |
03:43 ET | 308 | 6.09 |
03:45 ET | 1980 | 6.07 |
03:48 ET | 400 | 6.1 |
03:50 ET | 2323 | 6.08 |
03:52 ET | 1117 | 6.07 |
03:54 ET | 1500 | 6.07 |
03:56 ET | 600 | 6.07 |
03:57 ET | 1868 | 6.08 |
03:59 ET | 9140 | 6.1 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Syros Pharmaceuticals Inc | 154.2M | 4.0x | --- |
Genelux Corp | 167.3M | -5.4x | --- |
Celularity Inc | 123.7M | -0.5x | --- |
Adagene Inc | 124.7M | -3.4x | --- |
Clearside Biomedical Inc | 127.8M | -3.0x | --- |
Adicet Bio Inc | 140.3M | -0.6x | --- |
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company’s product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. It is also focused on the development for the treatment of multiple preclinical programs in oncology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $154.2M |
---|---|
Revenue (TTM) | $8.8M |
Shares Outstanding | 25.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.77 |
EPS | $1.52 |
Book Value | $6.30 |
P/E Ratio | 4.0x |
Price/Sales (TTM) | 17.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,567.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.